title: HIV/AIDS: recent advances in antiretroviral agents.
abstract: Despite the considerable progress in antiretroviral therapy, the eradication of HIV-1 remains unfeasible. Therefore, novel agents are under investigation. The aim of this review is to summarize the conventional compounds, to describe the recently approved agents, and to take a comprehensive look at the clinically relevant findings of current research.
authors: HIV Infection Office, Center for Diseases Control and Prevention, Athens, Greece.
authors: Georgios
authors: G
authors: Nikolopoulos
authors: Stefanos
authors: S
authors: Bonovas
authors: Argirios
authors: A
authors: Tsantes
authors: Nikolaos M
authors: NM
authors: Sitaras
mesh_terms: D000818:Animals; D019380:Anti-HIV Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D065100:CCR5 Receptor Antagonists; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D019429:Integrase Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D011480:Protease Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D019713:Receptors, CCR5 / Q000276:immunology; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors*; D018894:Reverse Transcriptase Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D019429:Integrase Inhibitors; D011480:Protease Inhibitors; D019713:Receptors, CCR5; D019718:Receptors, CXCR4; D018894:Reverse Transcriptase Inhibitors